[
    [
        {
            "time": "2020-12-29",
            "original_text": "午间公告：云南白药耗资18亿元回购1.31%公司股份；润建股份预中标1.03亿元广东联通采购项目",
            "features": {
                "keywords": [
                    "云南白药",
                    "回购",
                    "股份",
                    "18亿元"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "午间公告：云南白药耗资18亿元回购1.31%公司股份；润建股份预中标1.03亿元广东联通采购项目",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-12-29",
            "original_text": "云南白药：累计回购1.31%公司股份，耗资18亿元",
            "features": {
                "keywords": [
                    "云南白药",
                    "回购",
                    "股份",
                    "18亿元"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "云南白药：累计回购1.31%公司股份，耗资18亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-12-29",
            "original_text": "医药生物行业报告：继续重点关注创新核心竞争力和医药大消费两大投资方向",
            "features": {
                "keywords": [
                    "医药生物",
                    "创新",
                    "核心竞争力",
                    "医药大消费"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医药生物行业报告：继续重点关注创新核心竞争力和医药大消费两大投资方向",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-12-29",
            "original_text": "海外疫情引关注 “国谈”下创新药企业面临新考验",
            "features": {
                "keywords": [
                    "海外疫情",
                    "国谈",
                    "创新药",
                    "考验"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "海外疫情引关注 “国谈”下创新药企业面临新考验",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-12-29",
            "original_text": "云南白药已耗资18.08亿元累计回购1670万股 回购实施已完成",
            "features": {
                "keywords": [
                    "云南白药",
                    "回购",
                    "18.08亿元",
                    "1670万股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "云南白药已耗资18.08亿元累计回购1670万股 回购实施已完成",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        }
    ]
]